Principal Financial Group Inc. Has $7.92 Million Stake in Dynavax Technologies Corporation (NASDAQ:DVAX)

Principal Financial Group Inc. lifted its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 2.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 610,880 shares of the biopharmaceutical company’s stock after buying an additional 14,290 shares during the quarter. Principal Financial Group Inc. owned about 0.50% of Dynavax Technologies worth $7,923,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Deep Track Capital LP lifted its stake in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock valued at $227,197,000 after acquiring an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in shares of Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock worth $66,325,000 after buying an additional 5,172,263 shares during the last quarter. Norges Bank purchased a new position in shares of Dynavax Technologies in the 4th quarter worth about $7,762,000. D. E. Shaw & Co. Inc. boosted its holdings in shares of Dynavax Technologies by 34.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after buying an additional 486,981 shares during the last quarter. Finally, WINTON GROUP Ltd boosted its holdings in shares of Dynavax Technologies by 339.0% in the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 329,579 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Down 2.8%

DVAX stock opened at $10.44 on Wednesday. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $10.04 and its 200 day moving average is $11.76. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -20.08 and a beta of 1.03. Dynavax Technologies Corporation has a 1-year low of $9.22 and a 1-year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The business had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Sell-side analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. JMP Securities dropped their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. Wall Street Zen downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 6th. Finally, The Goldman Sachs Group decreased their price target on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.00.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.